Ask Warren

NeoImmuneTech

950220 · KOSDAQ · ₩950220 · 네오이뮨텍

₩1,670▲ ₩64 (3.99%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y −45.42%
Market cap
₩57B
Enterprise value
₩57B
P/E
—
P/B
1,562.1×
Dividend yield
0.0%
ROE
−46.5%
Net margin
−1,430.9%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−62.5% from the high

₩1,115Today: ₩1,616 – ₩1,718₩4,450

Returns

  • 1W−2.6%
  • 1M−11.5%
  • 3M+26.7%
  • 6M−29.7%
  • YTD−59.3%
  • 1Y−45.4%
Volume today
155,700
0.9× the 20-day average
Traded today
₩260M
Listed shares
34,211,840
EPS (12 months)
₩0
Earnings yield −0.0%
SellBuy
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

40Quiet
  • BuzzQuietBuzz 40 of 100 (50 is a normal day for this stock).
  • SentimentPositiveNews: Positive trial result reported by a news outlet, though it is a single company update. Community: 0 bullish, 0 bearish posts this week.
  • MomentumWeak-9.5% over the last month; the price is below its 20-day average.
  • News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.

Signals describe activity, not recommendations. Not financial advice.

NeoImmuneTech stock overview

NeoImmuneTech (네오이뮨텍, KRX: 950220) is listed on KOSDAQ, in the Biotech & Pharma sector. The company is a Korean biotechnology firm developing T-cell-based immunotherapies, with its lead pipeline NT-I7, a long-acting IL-7 family T-cell amplifier, in clinical development. Its shares closed at ₩1,670 on Oct 27, 2026, up 3.99% on the day, giving it a market value of ₩57B.

Key facts

Market cap
₩57B
Sector
Biotech & Pharma
Latest price change
+3.99%
As of
Oct 27, 2026
Main business
The company is a Korean biotechnology firm developing T-cell-based immunotherapies, with its lead pipeline NT-I7, a long-acting IL-7 family T-cell amplifier, in clinical development.

Quick answers about NeoImmuneTech

What does NeoImmuneTech do?
The company is a Korean biotechnology firm developing T-cell-based immunotherapies, with its lead pipeline NT-I7, a long-acting IL-7 family T-cell amplifier, in clinical development. Its research targets acute radiation syndrome and combination therapy with CAR-T cell treatments, alongside other immuno-oncology candidates built on its Heterodimer Fc antibody platform. The company generates revenue mainly through licensing, co-development partnerships, and government supply contracts, and it has secured exclusive North American rights to the approved sickle cell disease drug Endari.
What is the market cap of NeoImmuneTech?
The market capitalisation of NeoImmuneTech was ₩57B at the close on Oct 27, 2026.
Who are the largest shareholders of NeoImmuneTech?
According to the latest official filings, the largest reported holders are Genexine (16.29%, as of Jul 10, 2026); Muhrim-Bluewave 2nd New Technology Investment Partnership (14.93%, as of Sep 4, 2026); Ju Ji-young (0.09%, as of Aug 21, 2025).
When is the next earnings report from NeoImmuneTech?
Korean companies rarely announce results dates in advance. Based on when NeoImmuneTech filed the same report in past years, its next 3q results is expected between Nov 7, 2026 and Nov 14, 2026.

Company profile

The company is a Korean biotechnology firm developing T-cell-based immunotherapies, with its lead pipeline NT-I7, a long-acting IL-7 family T-cell amplifier, in clinical development. Its research targets acute radiation syndrome and combination therapy with CAR-T cell treatments, alongside other immuno-oncology candidates built on its Heterodimer Fc antibody platform. The company generates revenue mainly through licensing, co-development partnerships, and government supply contracts, and it has secured exclusive North American rights to the approved sickle cell disease drug Endari.

Written by AI from the company's latest annual report.

Korean name
네오이뮨텍
Sector
Biotech & Pharma
Themes
Biotech (new drugs)
CEO
김태경
Founded
Jan 2014
Listed
Mar 2021
Listed shares
34,211,840
Fiscal year ends
Month 12
Website
neoimmunetech.co.kr

Similar companies

Recent news

News · Chosun Biz·

NeoImmuneTech: 2-year survival rate 100% in high-dose NT-I7 group in US CAR-T combination trial; "full-scale technology transfer underway"

NeoImmuneTech₩1,670▲3.99%
Read the original ↗

Predicted impact: Low

Clinical trial survival data and technology transfer talk; no contract value or revenue size disclosed.

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: NeoImmuneTech / 네오이뮨텍 / 950220 / KRX:950220

Source: KRX statistical information